During the past decade, Samodzielny Publiczny Centralny Szpital Kliniczny conducted 31 clinical trials. In the 10-year time frame, 31 clinical trials started and 22 clinical trials were completed, i.e. on average, 71% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 12 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Samodzielny Publiczny Centralny Szpital Kliniczny" #1 sponsor was "Ipsen" with 6 trials, followed by "Pfizer" with 5 trials sponsored, "BackBeat Medical Inc" with 3 trials sponsored, "Bayer" with 3 trials sponsored and "Celgene" with 3 trials sponsored. Other sponsors include 25 different institutions and companies that sponsored additional 31 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Samodzielny Publiczny Centralny Szpital Kliniczny" #1 collaborator was "Basilea Pharmaceutica International Ltd" with 2 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "MLM Medical Labs GmbH" with 2 trials as a collaborator, "Massachusetts General Hospital" with 2 trials as a collaborator and "nabios GmbH" with 2 trials as a collaborator. Other collaborators include 22 different institutions and companies that were collaborators in the rest 32 trials.

According to Clinical.Site data, the most researched conditions in "Samodzielny Publiczny Centralny Szpital Kliniczny" are "Alzheimer Disease" (3 trials), "Aspergillosis" (2 trials), "Atrial Fibrillation" (2 trials), "Atrioventricular Block" (2 trials) and "Duchenne Muscular Dystrophy" (2 trials). Many other conditions were trialed in "Samodzielny Publiczny Centralny Szpital Kliniczny" in a lesser frequency.

Most popular intervention types in "Samodzielny Publiczny Centralny Szpital Kliniczny" are "Drug" (39 trials), "Other" (7 trials), "Biological" (6 trials), "Device" (5 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (18 trials), "Botulinum toxin type A" (5 trials), "placebo" (3 trials), "Elranatamab" (2 trials) and "Rituximab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Samodzielny Publiczny Centralny Szpital Kliniczny" are 46 trials for "All" genders, 3 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are 17 active trials in "Samodzielny Publiczny Centralny Szpital Kliniczny". 1 are not yet recruiting, 7 are recruiting, 7 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 25 completed trials in Samodzielny Publiczny Centralny Szpital Kliniczny, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Samodzielny Publiczny Centralny Szpital Kliniczny, 1 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 32 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".

Samodzielny Publiczny Centralny Szpital Kliniczny has several departments that took part in Clinical trials: "Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie; Klinika Neurologii" - 2 trials